Carine San

Dr. Carine San

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 June 2018 in Molecules
Verified
Journal Article
Open access
PDF file
NVNicolas Vignal
Nicolas Vignal
Salvatore CisterninoSalvatore Cisternino
Salvatore Cisternino
NRNathalie Rizzo-Padoin
Nathalie Rizzo-Padoin
CSCarine San
Carine San
FHFortune Hontonnou
Fortune Hontonnou
BHBenoît Hosten
Benoît Hosten
[18F]FEPPA is a specific ligand for the translocator protein of 18 kDa (TSPO) used as a positron emission tomography (PET) biomarker for glial activation and neuroinflammation. [18F]FEPPA radiosynthesis was optimized to assess in a mouse model the cerebral inflammation induced by an intraperitoneal injection of Salmonella enterica serovar Typhimurium lipopolysaccharides (LPS; 5 mg/kg) 24 h before PET imaging. [18F]FEPPA was synthesized by nucleophilic substitution (90 °C, 10 min) with tosylated precursor, followed by improved semi-preparative HPLC purification (retention time 14 min). [18F]FEPPA radiosynthesis were carried out in 55 min (from EOB). The non-decay corrected radiochemical yield were 34 ± 2% (n = 17), and the radiochemical purity greater than 99%, with a molar activity of 198 ± 125 GBq/µmol at the end of synthesis. Western blot analysis demonstrated a 2.2-fold increase in TSPO brain expression in the LPS treated mice compared to controls. This was consistent with the significant increase of [18F]FEPPA brain total volume of distribution (VT) estimated with pharmacokinetic modelling. In conclusion, [18F]FEPPA radiosynthesis was implemented with high yields. The new purification/formulation with only class 3 solvents is more suitable for in vivo studies.

7 February 2020 in Cells
Verified
Journal Article
Open access
PDF file
NVNicolas Vignal
Nicolas Vignal
ABAnne-Cécile Boulay
Anne-Cécile Boulay
CSCarine San
Carine San
MCMartine Cohen-salmon
Martine Cohen-salmon
NRNathalie Rizzo-Padoin
Nathalie Rizzo-Padoin
BHBenoît Hosten
Benoît Hosten
Astroglial connexin 43 (Cx43) has been recognized as a crucial immunoregulating factor in the brain. Its inactivation leads to a continuous immune recruitment, cytokine expression modification and a specific humoral autoimmune response against the astrocytic extracellular matrix but without brain lesions or cell lysis. To assess the impact of Cx43 deletion on the brain’s inflammatory response, TSPO expression was studied by positron emission tomography (PET) imaging with a specific radioligand, [18F]FEPPA, in basal conditions or upon Lipopolysaccharides (LPS)-induced inflammatory challenge. Astroglial Cx43-deleted mice underwent [18F]FEPPA PET/CT dynamic imaging with or without LPS injection (5 mg/kg) 24 h before imaging. Quantification and pharmacokinetic data modelling with a 2TCM-1K compartment model were performed. After collecting the mice brains, TSPO expression was quantified and localized by Western blot and FISH analysis. We found that astroglial Cx43 deficiency does not significantly alter TSPO expression in the basal state as observed with [18F]FEPPA PET imaging, FISH and Western blot analysis. However, deletion of astrocyte Cx43 abolishes the LPS-induced TSPO increase. Autoimmune encephalopathy observed in astroglial Cx43-deleted mice does not involve TSPO overexpression. Consistent with previous studies showing a unique inflammatory status in the absence of astrocyte Cx43, we show that a deficient expression of astrocytic Cx43 protects the animals from LPS-induced neuroinflammation as addressed by TSPO expression.

31 October 2023 in Chemistry – A European Journal
Verified
Journal Article
Open access
CSCarine San
Carine San
BHBenoît Hosten
Benoît Hosten
NVNicolas Vignal
Nicolas Vignal
MBMeriem Beddek
Meriem Beddek
MPMaurice Pillet
Maurice Pillet
FDFabienne Dioury
Fabienne Dioury
Fluorine‐18 (18F) is the most favorable positron emitter for radiolabeling Positron Emission Tomography (PET) probes. However, conventional 18F labeling through covalent C−F bond formation is challenging, involving multiple steps and stringent conditions unsuitable for sensitive biomolecular probes whose integrity may be altered. Over the past decade, an elegant new approach has been developed involving the coordination of an aluminum fluoride {Al18F} species in aqueous media at a late‐stage of the synthetic process. The objective of this study was to implement this method and to optimize radiolabeling efficiency using a Design of Experiments (DoE). To assess the impact of various experimental parameters on {Al18F} incorporation, a pentadentate chelating agent NODA‐MP‐C4 was prepared as a model compound. This model carried a thiourea function present in the final conjugates resulting from the grafting of the chelating agent onto the probe. The formation of the radioactive complex Al18F‐NODA‐MP‐C4 was studied to achieve the highest radiochemical conversion. A complementary “cold” series study using the natural isotope 19F was also conducted to guide the radiochemical operating conditions. Ultimately, Al18F‐NODA‐MP‐C4 was obtained with a reproducible and satisfactory radiochemical conversion of 79±3.5 % (n=5).

9 November 2024 in Chemistry – A European Journal
Verified
Journal Article
Open access
FDFabienne Dioury
Fabienne Dioury
CSCarine San
Carine San
GGGayathiri Gnanalingam
Gayathiri Gnanalingam
CHCeline Henoumont
Celine Henoumont
Yoann RousselinYoann Rousselin
Yoann Rousselin
MPMarc Port
Marc Port
Positron Emission Tomography (PET) is used in oncology for tumor diagnosis, commonly relying on fluorine‐18 (18F) emission detection. The conventional method of 18F incorporation on to probes by covalent bonding is harsh for sensitive biomolecules, which are nonetheless compounds of choice for the development of targeted probes. This study explores gallium–18F (Ga18F) coordination, a milder alternative method occurring in aqueous media at the final stage of radiosyntheses. Pyclen‐based chelating agents were proposed to capture (GaF) species at room temperature and pH≥5 making the radiofluorination process compatible with heat‐ and acid‐sensitive biomolecules. Highly promising results were obtained with the PC2A–based chelating agent LH2 derived from the new bifunctional PC2A–OAE–NCS compound. The solid‐state structure of GaF(L) was elucidated by X‐ray diffraction and revealed an unconventional heptacoordination of Ga(III). A high radiochemical conversion (RCC) of 86 % was achieved at room temperature, in water at pH 5 within 20 minutes. Stability studies showed the robustness of the GaF(L) complex in aqueous media for at least one day and at least one hour for the radiolabeled analog Ga18F(L). These findings demonstrated that PC2A‐based compounds are chelating agents of choice for (Ga18F) species, suggesting a real technological breakthrough for PET imaging and precision medicine.

8 April 2026
Verified
Thesis
Closed access
CSCarine San
Carine San
La Tomographie par Emission de Positons (TEP) est une technique d'imagerie médicale pratiquée en milieu hospitalier dans les services de médecine nucléaire. Elle est utilisée en cancérologie pour le diagnostic et le suivi thérapeutique de traitements anticancéreux car elle est très sensible pour détecter des tumeurs de petites tailles. A l’heure de la médecine personnalisée, les radiotraceurs à base de biomolécules intéressent grandement les cliniciens. En effet, la spécificité et affinité inégalées des biomolécules pour les organes/tissus pathogènes en font des traceurs de choix. Cependant, la méthode conventionnelle de radiomarquage se fait dans des conditions qui dénaturent ces biomolécules. L’objectif de ce projet est de lever ce verrou et de développer une méthode alternative plus douce basée sur la chimie de coordination de l’espèce gallium-18F peu explorée à ce jour. La méthode alternative proposée ici sera optimisée selon une méthodologie basée sur une solution statistique par Plans d’Expériences. Ce projet relève du domaine de la thérapie ciblée et est à fort potentiel de valorisation ; il vise à développer une nouvelle méthode de préparation de radiotraceurs plus spécifiques des différents types de cancers avec comme finalité ultime un dépistage plus précoce et le développement d’outils de médecine de précision.